Videos

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.

A panel of experts from City of Hope and satellite clinics review the available frontline therapy options for patients with transplant-eligible newly diagnosed multiple myeloma.

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with transplant-eligible newly diagnosed multiple myeloma to the panel for discussion.

Luspatercept, which is now FDA approved for myelodysplastic syndromes, may help patients achieve transfusion independence.

Experts discuss the second-line treatment options for chronic graft-vs-host disease when steroids fail, including ruxolitinib.

Erin Kopp, NP, emphasizes the importance of identifying patient response to steroids, establishing steroid dependence, and using a systematic tapering regimen for effective management of chronic graft-vs-host disease.

Key opinion leaders in the field of renal cell carcinoma management reflect on recent data with IO/TKI combination therapy in patients with non-clear cell disease.

Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.

Focusing on immunotherapy management for metastatic bladder cancer, Dr Shah shares notable toxicities, relevant real-world data, and emergent data on maintenance therapy.

Dr Jain discusses latest data in frontline and maintenance therapy for metastatic bladder cancer and Mr. Ehas shares his experiences during the course of his treatment.

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.

Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.

The panel reviews treatment approaches for graft-versus-host disease when steroids are not an option and explains how the heterogeneity of GVHD makes finding the right treatment challenging.

Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.

In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.

Key opinion leaders highlight the variable symptoms of chronic graft-versus-host disease and the importance of educating patients and community physicians to recognize and address early signs.

Expert perspectives on novel treatment strategies in the second-line treatment setting of advanced bladder cancer.

Mr. Ehas shares his initial treatment experience and response to chemo, while Anand Shah, PharmD, BCOP describes an oncology pharmacists’ role in patient education and adverse event management.

Dr Jain discusses frontline treatment options, cisplatin eligibility criteria, and therapy considerations for metastatic bladder cancer.

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.

Experts discuss the challenges of grading chronic graft-versus-host disease using NIH criteria, noting the importance of a common language, and considering patient symptoms, performance status, and organ involvement in assessing severity.